|drug2306||Omega 3/Nigella Sativa Oil/Quinine pills Wiki||1.00|
|drug151||Active Comparator Wiki||1.00|
|drug2305||Omega 3/Nigella Sativa Oil/Indian Costus Wiki||1.00|
|D007153||Immunologic Deficiency Syndromes NIH||0.41|
There is one clinical trial.
The first version of this preprint article is registered on the 4th of May 2020 under the digital object identifier of:10.31219/osf.io/u56fc. COVID-19 infections virus spread worldwide and impact many countries with sever economical sequences. The effective antiviral medication or vaccination for the virus is unavailable until the present date and it takes months or years to discover the effective treatment or test the efficacy of the discovered treatment. Based on these facts, the human immune system against the virus may have an effective role to regulate the infection and reduce the mortality rate among the infected patients. This proposed research article aims to explore the available medication/ natural supplementation to boost the immunity system of the patients against COVID-19 infections and reduce the mortality rate among infected patients. Methods: a proposed clinical trial will be carried out to investigate the effect of the different treatment modalities on the human immune system against COVID-19 infection.
Description: Time to Clinical recoveryMeasure: Clinical improvement Time: 30 Days
Description: Percentage of patients returned to negative swaps of COVID-19Measure: Recovery rate from positive to negative swaps Time: 14 Days
Description: Number of days for fever remission T=37.5°CMeasure: Fever to normal temperature in days Time: 15 Days
Description: Number of days to report lungs recovery in chest X ray or CTMeasure: Remission of lung inflammation in CT or X-ray Time: 30 Days
Description: Number of days for hospitalizationMeasure: Length of hospitalization Time: 10 Days
Description: Change of (PCR levels) > 50% in comparison with PCR levels at the admissionMeasure: (PCR levels) polymerase chain reaction assay levels Time: 10 Days
Description: P O2/Fi O2 which reflects patients' oxygen saturationMeasure: Respiratory indexes Time: 10 Days
Description: C-reactive protein milligrams per deciliter correlated with inflammationMeasure: C-reactive protein mg/L Time: 25 Days
Description: Serum Ferritin Nanograms per milliliter correlated with iron overload and illness severityMeasure: Serum Ferritin ng/ml Time: 25 Days
Description: Lactic acid dehydrogenase unit per litter correlated with illness severityMeasure: Lactic acid dehydrogenase U/L Time: 25 Days
Description: leukocytes in microliter correlated with mortalityMeasure: leukocytes count μl Time: 30 Days
Description: Mg/dl correlated with lipid peroxidation that linked to oxidative stressMeasure: Lipid profile [LDL, HDL, Total cholesterol ] Time: 14 Days
Description: Evaluate the antioxidant response against the free radicals produced in COVID-19 infection measured by ELISAMeasure: total plasma antioxidant capacity Time: 14 Days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports